L'OTI non è una panacea per tutti i mali, ma trova precisa e netta indicazione in tutte quelle patologie che riconoscono una diminuzione della tensione di Ossigeno a livello tissutale, insufficiente all'espletamento delle funzioni vitali, cioè sfruttando l'aumento delle pressioni e della quantità di Ossigeno disciolto nel plasma secondo leggi fisiche dei gas. La Società Italiana di Medicina Subacquea e Iperbarica (SIMSI) raccomanda che i quadri clinici in cui l'OTI non sia considerata di provata efficacia, o non siano ancora inseriti nelle indicazioni contenute nelle Linee Guida di riferimento, dovranno essere sempre preventivamente valutati per ogni specifico paziente in base al possibile beneficio rapportato al rischio e al costo del trattamento, nel rispetto della salute e della libertà dei pazienti, della buona pratica clinica nella nostra disciplina, del codice etico e deontologico della professione medica." PREMESSA OSSIGENO IPERBARICO: COME
OTI Therapies
The Società Italiana di Medicina Subacquea ed Iperbarica (SIMSI) is actively commiitted ed to promoting the spread of hyperbaric oxygen therapy (HBO2). In Italy HBO2 is included in the Essential Levels of Care – the benefits guaranteed by the state to all citizens – using code 93.95, which has a value of € 81-120 per treatment. This is is for a scheduled 90-minute treatment for a seated non-critical patient, including medical or nursing assistance. The Italian market is managed by 50 hyperbaric centers that produce 150,000 HBO2 treatments per year, for an estimated value of around €20 million. In Italy the 10 main private companies in health care have not yet invested in hyperbaric medicine, as they are likely unaware of the potential (i.e., pro table/positive gross contribution margin). A “technology push” marketing approach may help with awareness. Regarding technology, Italian legislation currently exists only for multiplace hyperbaric chambers. SIMSI, through the Institute of Clinical Physiology (IFC) of the National Council for Research (CNR), has created a web portal as a tool that aims to facilitate understanding among manufacturers, operators and users.
Articles News
-
Characterizing Immersion Pulmonary Edema (IPE): A Comparative Study of Military and Recreational Divers
CONCLUSION: It seems that the occurrence of IPE in young and healthy individuals requires their engagement in vigorous physical activity. Additionally, exposure to significant[…]
Read more... -
Dissolved gases from pressure changes in the lungs elicit an immune response in human peripheral blood
Conventional dogma suggests that decompression sickness (DCS) is caused by nitrogen bubble nucleation in the blood vessels and/or tissues; however, the abundance of bubbles[…]
Read more... -
Hyperbaric Oxygen Therapy Counters Oxidative Stress/Inflammation-Driven Symptoms in Long COVID-19 Patients: Preliminary Outcomes
Long COVID-19 patients show systemic inflammation and persistent symptoms such as fatigue and malaise, profoundly affecting their quality of life. Since improving oxygenation can[…]
Read more... -
Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials
CONCLUSIONS AND RELEVANCE: In hospitalized patients with COVID-19, vitamin C had low probability of improving the primary composite outcome of organ support-free days and[…]
Read more... -
Cardiopulmonary resuscitation during hyperbaric oxygen therapy: a comprehensive review and recommendations for practice
CONCLUSIONS: CPR in the context of HBOT is a rare, yet critical event requiring special considerations. Existing guidelines should be adapted to address these[…]
Read more...